Financial Review: Neuphoria Therapeutics (NASDAQ:NEUP) & Invivyd (NASDAQ:IVVD)

Neuphoria Therapeutics (NASDAQ:NEUP) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Insider and Institutional Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 12.2% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Neuphoria Therapeutics and Invivyd’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Invivyd	-183.90%	-59.73%	-48.97%

Earnings and Valuation

This table compares Neuphoria Therapeutics and Invivyd”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17 million	14.01	-$13.45 million	($6.22)	-0.49
Invivyd	$58.37 million	2.93	-$52.49 million	($0.33)	-1.76

Neuphoria Therapeutics has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Neuphoria Therapeutics and Invivyd, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
Invivyd	1	2	3	0	2.33

Neuphoria Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 130.26%. Invivyd has a consensus target price of $10.00, suggesting a potential upside of 1,624.14%. Given Invivyd’s stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Neuphoria Therapeutics.

Summary

Invivyd beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.